Combination therapy of bryostatin and CD22-CAR-T cells increases the CAR-T cell activity by increasing CD22 expression and sensitizing leukemia cells to CAR-T cell antigen-non-specific killing (31). The gene discussed is CD22; the disease is leukemia.